DRTSW
Alpha Tau Medical Ltd. Warrant
stock NASDAQ Warrant

I am long DRTS and it’s a very, very unique front run opportunity for retail investors (vs. institutional investors that couldn’t get in because of low liquidity.)
Whats the idea? Their alpha radiation platform works on physics, rather than chemistry. High LET radiation placed directly into the tumor destroys the tumors double helix DNA and releases the antigens that signal the bodies T cells.
The platform has been tested against north of 300+ people across nearly every solid tumor and there are no side effects. They recently achieved the challenging PMDA certification in Japan and are now working five separate IDEs with the FDA.
There is no revenue yet but that’s by design. With a platform like this, you only get a first attempt to negotiate insurance reimbursement and you always lead with your best. Their best is a recurring GBM (brain cancer) that is halfway through a trial at this moment and the results so far are nothing short of breath taking.
No other treatment has ever achieved two Complete Responses against rGBM and Alpha Tau did it two out of the first three cases. Remember: there is NO standard of care for rGBM. They send in a social worker and tell you to say goodbye. Alpha Tau could wind up as the standard of care for rGBM globally.
Then, you have to do math.
Lets say they charge $120k per treatment (which is a simple, biopsy like outpatient procedure that thrills insurance companies) and they are all alone for inoperable brain cancer. Whats that worth?
$5B? $20B? $50B?
Now, take a look at their current market cap before the big institutions get in.
$1.13B.
Massive ownership from the C suite so interests are aligned.
Fully funded through 2027.
Massive US commercial agreement with Tolmar around prostate cancer.
And potentially the biggest IDE is yet to happen with the FDA: Alpha Tau has demonstrated the ability to fix the blind spot of the $50B checkpoint inhibitor market. The IDE once approved will allow Alpha Tau to trial in combination with Keytruda, Merck’s $32B/year drug that boosts T cells. The blind spot for all checkpoint inhibitors is “cold tumors.” The Alpha Tau destruction of solid tumors turns cold tumors hot and that means no solid tumor is safe from the combination.
What’s that worth?
$50B? $100B? $250B?
Alpha Tau is sitting at $1.13B today.
But not for long.
One bonus point: this is a device. This is not a drug. There is no lengthy phase III. Its a safer play then betting on the chemistry of drugs.
I am long both DRTS and DRTSW.

DRTSW, RVMDW, AIRJW, ASTS, SIVEF, AUR. Average 5X by Christmas 2028.